September 29, 2006

SpeculatingStocks.com Stock Pick: Medivation, Inc. (MDV)

Stock Price: $8.94 (long-term strong buy)

Medivation, Inc. acquires promising pharmaceutical and medical device technologies in the late preclinical development phase, and develops those technologies. Depending on the indication from trials, Medivation either will seek to sell or partner successful programs with larger pharmaceutical, biotechnology and medical device companies for late-stage clinical studies and commercialization, or will conduct those activities internally.

MDV recently released stunning results on its proprietary drug Dimebon(TM). The Alzheimer's drug met all five efficacy endpoints in a six-month randomized, double-blinded, placebo-controlled Phase 2 clinical study of 183 patients with mild to moderate Alzheimer's disease conducted at 11 sites in Russia.

It is extremely rare for an Alzheimer's Phase 2 study to demonstrate such statistical significance on all of the primary and secondary endpoints.

We believe Dimebon(TM) has a great start to possibly becoming a major Alzheimer's drug. The Alzheimer's drug market is expected to hit $4.0 billion annually by 2013 according to analysts.

Medivation has just received permission from the FDA to begin its U.S. phase 1-2a clinical trial of Dimebon(TM) in patients with Huntington's disease.

Investors gapped MDV higher to the $8.00 level after the Dimebon(TM) Alzheimer results. The demand for the stock has been huge ever since at the higher level trading multiple times average volume.

SpeculatingStocks.com Target Price: We expect MDV to reach $18.00 within the next 6 - 12 month with strong upside surprises possible.